{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:41:16Z","timestamp":1792442476766,"version":"4.5.0"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Med Imag Rad Onc"],"published-print":{"date-parts":[[2014,4]]},"abstract":"Abstract<\/jats:title>Introduction<\/jats:title>Fluorodeoxyglucose positron emission tomography (FDG PET<\/jats:styled-content>) is not recommended in early stage melanoma; however, a significant number of cases are referred to our institution for FDG PET<\/jats:styled-content>. We refer to early stage disease as A<\/jats:styled-content>merican J<\/jats:styled-content>oint C<\/jats:styled-content>ommittee on C<\/jats:styled-content>ancer (AJCC<\/jats:styled-content>) stage I<\/jats:styled-content> and II<\/jats:styled-content>, which includes all cases without metastases. A retrospective review was undertaken to determine the clinical utility of FDG PET<\/jats:styled-content> in this patient group.<\/jats:p><\/jats:sec>Methods<\/jats:title>A retrospective study of FDG<\/jats:styled-content> scans on all patients presenting to the WA PET<\/jats:styled-content> Centre with early stage melanoma over a 5\u00bd year period was undertaken. The positivity rate of the initial study for detection of malignant melanoma was determined. In patients with an initially negative FDG PET<\/jats:styled-content>, the time from initial diagnosis to a positive surveillance study was determined. Both the initial positivity rate and time to a positive study were correlated with B<\/jats:styled-content>reslow staging.<\/jats:p><\/jats:sec>Results<\/jats:title>Three hundred twenty\u2010two patients were included in the study, of which 74 had initial positive FDG PET<\/jats:styled-content> scans (23%). Adequate follow\u2010up was available in 51 patients with the PET<\/jats:styled-content> result confirmed as true positive in 37 (positive predictive value 73%). One hundred eight of 248 patients initially negative had follow\u2010up scans during the follow\u2010up period, of which 48 became positive. The 73% of recurrences were over 12 months post\u2010diagnosis. No correlation with Breslow thickness was demonstrated.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Despite FDG PET<\/jats:styled-content> not being recommended for early cutaneous malignant melanoma, 27% of melanoma cases referred for FDG PET<\/jats:styled-content> during the study period were AJCC<\/jats:styled-content> stage I<\/jats:styled-content> or II<\/jats:styled-content>. Our results suggest FDG PET<\/jats:styled-content> in early stage melanoma demonstrates occult disease in 17% of cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1754-9485.12173","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T01:54:19Z","timestamp":1396403659000},"page":"149-154","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["FDG PET<\/scp> in early stage cutaneous malignant melanoma"],"prefix":"10.1111","volume":"58","author":[{"given":"Jody","family":"McIvor","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine Royal Perth Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teck","family":"Siew","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Royal Perth Hospital Perth Western Australia Australia"},{"name":"Department of Diagnostic and Interventional Radiology Royal Perth Hospital Perth Western Australia Australia"},{"name":"Nuclear Medicine and PET service Sir Charles Gairdner Hospital Perth Western Australia Australia"},{"name":"Fremantle Medical School University of Notre Dame Perth Western Australia Australia"},{"name":"University of Western Australia Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medical Engineering & Physics Royal Perth Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine Royal Perth Hospital Perth Western Australia Australia"},{"name":"Nuclear Medicine and PET service Sir Charles Gairdner Hospital Perth Western Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,4]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Australian Cancer Council.Melanoma. [Cited 18 Mar 2014.] Available from URL:http:\/\/www.cancer.org.au."},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-88441-7_31"},{"key":"e_1_2_6_4_1","unstructured":"Australian Cancer Network Melanoma Guidelines Revision Working Party.Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Cancer Council Australia and Australian Cancer Network Sydney and New Zealand Guidelines Group Wellington (2008)."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2493080240"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2011.01.001"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21189"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.10.2674"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.141.3.284"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04312.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2004.01130.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpet.2010.12.004"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2252::AID-CNCR12>3.0.CO;2-Q"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2003.09.016"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.16.3622"}],"container-title":["Journal of Medical Imaging and Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1754-9485.12173","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1754-9485.12173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:35:10Z","timestamp":1696246510000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1754-9485.12173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1111\/1754-9485.12173"],"URL":"https:\/\/doi.org\/10.1111\/1754-9485.12173","archive":["Portico"],"relation":{},"ISSN":["1754-9477","1754-9485"],"issn-type":[{"value":"1754-9477","type":"print"},{"value":"1754-9485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"2014-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}